Quetiapine, olanzapine, risperidone, ziprasidone

Quetiapine, olanzapine, risperidone, ziprasidone

• A. Clozapine, olanzapine, quetiapine, risperidone
• B. Adjunctive treatment for MDD
• C. Tardive dyskinesia treatment
• D. Antagonism in dopaminergic pathways

Answer: (B)

These drugs illustrate how atypical antipsychotics can be used to augment antidepressant therapy in major depressive disorder when a patient doesn’t respond fully to antidepressants alone. Quetiapine, olanzapine, risperidone, and ziprasidone help modulate mood, anxiety, and sleep through their effects on dopamine and serotonin systems, which can enhance overall antidepressant response. For example, quetiapine’s active metabolite norquetiapine provides noradrenergic reuptake inhibition and 5-HT1A partial agonism, contributing to antidepressant augmentation. Olanzapine in combination with fluoxetine is a recognized augmentation approach for treatment-resistant depression, and risperidone and ziprasidone also have evidence supporting their use as add-on options. Clozapine is mainly for treatment-resistant schizophrenia, tardive dyskinesia is a potential side effect rather than an indication, and dopaminergic antagonism describes a general mechanism rather than the specific therapeutic role here.

These drugs illustrate how atypical antipsychotics can be used to augment antidepressant therapy in major depressive disorder when a patient doesn’t respond fully to antidepressants alone. Quetiapine, olanzapine, risperidone, and ziprasidone help modulate mood, anxiety, and sleep through their effects on dopamine and serotonin systems, which can enhance overall antidepressant response. For example, quetiapine’s active metabolite norquetiapine provides noradrenergic reuptake inhibition and 5-HT1A partial agonism, contributing to antidepressant augmentation. Olanzapine in combination with fluoxetine is a recognized augmentation approach for treatment-resistant depression, and risperidone and ziprasidone also have evidence supporting their use as add-on options. Clozapine is mainly for treatment-resistant schizophrenia, tardive dyskinesia is a potential side effect rather than an indication, and dopaminergic antagonism describes a general mechanism rather than the specific therapeutic role here.